Figure 7.
Development of five membered heterocycle-based peptidomimtic inhibitors 27–31. Inhibitors were developed by divalent classical bioisosterism replacement of position 4 methylene unit in previously designed inhibitors with either ether or sulfone moiety. IC50 refers to inhibition of plasmin amidolysis.